-

Shareholder Alert: Robbins LLP is Investigating GoodRx Holdings, Inc. (GDRX) on Behalf of Shareholders

SAN DIEGO & SANTA MONICA, Calif.--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP is investigating GoodRx Holdings, Inc. (NASDAQ: GDRX) on behalf of shareholders to determine whether certain GoodRx officers and directors violated the Securities Exchange Act of 1934 and breached their fiduciary duties to the Company. GoodRx is a holding company that owns and operates a U.S. consumer-focused digital healthcare platform.

If you suffered a loss due to GoodRx Holdings, Inc.'s misconduct, click here.

GoodRx Holdings, Inc. (GDRX) Misled Shareholders Regarding its Business Prospects

According to a class action complaint filed against GoodRx, Defendants timed the Company's initial public offering ("IPO") to happen just before Amazon.com, Inc. announced its online pharmaceutical business that would compete with GoodRx, which maximized the amount of money the selling stockholders could raise in the IPO and artificially inflated GoodRx's stock price.

GoodRx closed its IPO on September 25, 2020, selling 39.8 million shares for $33 per share, generating over $1.3 billion in gross offering proceeds. In its Registration Statement, GoodRx touted its successes in growing market share and stated that it is "a market leader with a significant scale and brand advantage over our competitors. Our growth accelerates self-reinforcing network effects that further strengthen our competitive position." However, at the time these statements were made, defendants knew that Amazon was about to enter the online prescription medication ordering and fulfillment business because of the Company's close relationship with Amazon and reliance on Amazon Web Services to support the Company's platform. On November 17, 2020, Amazon announced two new pharmacy offerings, which would compete directly with GoodRx's platform. On this news, GoodRx's stock declined 23%, erasing more than $4 billion of the Company's market capitalization.

GoodRx Holdings, Inc. (GDRX) shareholders have legal options. All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

Contact us to learn more:
Lauren Levi
(800) 350-6003
llevi@robbinsllp.com
Shareholder Information Form

Robbins LLP is a nationally recognized leader in shareholder rights law. To be notified if a class action against GoodRx Holdings, Inc. settles or to receive free alerts about companies engaged in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Lauren Levi
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
llevi@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

More News From Robbins LLP

Robbins LLP Urges BBNX Stockholders Who Lost Money Investing in Beta Bionics, Inc. to Contact the Firm for Information About Leading the Class Action

SAN DIEGO--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP reminds investors that a class action was filed on behalf of all persons and entities who purchased or otherwise acquired Beta Bionics, Inc. (NASDAQ: BBNX) common stock between July 30, 2025 and February 24, 2026, inclusive (the "Class Period"). Beta Bionics is a commercial-stage medical device company that offers an automated insulin delivery system for the treatment of diabetes, known as the iLet Bionic Pancreas insulin pump (...

Robbins LLP Urges HIMS Stockholders Who Lost Money Investing in Hims & Hers Health, Inc. to Contact the Firm for Information About Leading the Class Action

SAN DIEGO--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP reminds investors that a class action was filed on behalf of all persons and entities who purchased or otherwise acquired Hims & Hers Health, Inc. (NYSE: HIMS) securities between August 4, 2025 and July 29, 2026, inclusive (the "Class Period"). Hims operates a health and wellness platform that connects consumers to licensed healthcare professionals.The complaint alleges that Hims & Hers shared customers' protected health...

Robbins LLP Urges UNCY Stockholders Who Lost Money Investing in Unicycive Therapeutics, Inc. to Contact the Firm for Information About Leading the Class Action

SAN DIEGO--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP reminds investors that a class action was filed on behalf of persons and entities who purchased or otherwise acquired Unicycive Therapeutics, Inc. (NASDAQ: UNCY) securities between December 29, 2025 and June 29, 2026. Unicycive is a clinical-stage biotechnology company that identifies, develops, and commercializes therapies for the treatment of kidney diseases.The complaint alleges that Unicycive failed to properly inspect its t...
Back to Newsroom